Failure of aminooxyacetic acid therapy in Huntington disease

@article{Perry1980FailureOA,
  title={Failure of aminooxyacetic acid therapy in Huntington disease},
  author={Thomas L. Perry and J. Michael Wright and Shirley Hansen and B M Allan and PatriciaA. Baird and Patrick M. Macleod},
  journal={Neurology},
  year={1980},
  volume={30},
  pages={772 - 772}
}
Seven patients with Huntington disease were treated with aminooxyacetic acid (AOAA), an inhibitor of μgM-aminobutyric acid aminotransferase (GABA-T), in an effort to alleviate symptoms by increasing brain GABA content. AOAA was given orally in a placebo-controlled crossover trial in which patients, relatives, and three of the evaluating physicians remained blind. Toxic symptoms occurred in all seven patients when AOAA dosage was increased beyond 2 mg per kilogram per day, and included… 

Tables from this paper

A double‐blind clinical trial of isoniazid in Huntington disease
TLDR
Lack of clinical improvement in most HD patients despite elevation of brain GABA content suggests that in the minority who are benefited, INH may be acting by some mechanism other than increase of GABAergic neuronal function.
THIP treatment of Huntington's disease
TLDR
CSF content of homovanillic acid, a major metabolite of dopamine, increased during high-dose THIP therapy, suggesting that augmentation of dopamine function may have contributed to the drug's lack of efficacy.
Emergingdrugtherapiesin Huntington'sdisease
TLDR
This review discusses the treatments now used for Huntington's disease before evaluating the newer drugs at present being explored in both the clinic and in the laboratory in mouse models of the disease.
Emerging drug therapies in Huntington's disease
TLDR
This review discusses the treatments now used for Huntington's disease before evaluating the newer drugs at present being explored in both the clinic and in the laboratory in mouse models of the disease.
A review of the treatment options for Huntington’s disease
TLDR
Huntington’s disease is an autosomal dominant, inherited, neuropsychiatric disease which gives rise to progressive motor, cognitive and behavioural symptoms, and the only treatment options available in HD are symptomatic.
Huntington's disease: present treatments and future therapeutic modalities
TLDR
There is definitely poor evidence in management of Huntington's disease, and riluzole, olanzapine and amantadine are recommended for the treatment of the movement disorders associated with HD, selective serotonin reuptake inhibitors and mirtazapine for the Treatment of depression, and atypical antipsychotic drugs for HD psychosis and behavioural problems.
Therapeutic interventions for symptomatic treatment in Huntington's disease.
TLDR
No intervention proved to have a consistent symptomatic control in HD, and tetrabenazine is the anti-choreic drug with the best quality data available.
Huntington’s Disease
Some ethical problems in Huntington's chorea.
  • T. Perry
  • Medicine, Psychology
    Canadian Medical Association journal
  • 1981
TLDR
Long experience with patients and their families during research on the biochemical basis of Huntington's chorea prompts me to raise some ethical issues that I think merit greater discussion by physicians and other health care professionals who deal with these families.
...
...

References

SHOWING 1-10 OF 16 REFERENCES
Huntington's disease. Cerebrospinal fluid GABA levels in at-risk individuals.
TLDR
The data indicate that low GABA levels in CSF are evident prior to the onset of symptoms of HD but a predictive value can only be determined by continued observation of the clinical course of these at-risk individuals.
SUSTAINED DRUG‐INDUCED ELEVATION OF BRAIN GABA IN THE RAT 1
TLDR
Brain GABA levels in the rat were increased by approx.
Gamma‐aminobutyric acid determination in human cerebrospinal fluid by mass‐fragmentography
TLDR
A specific and sensitive method for the quantification of GABA in human CSF has been developed and is presented at the fourth international symposium on mass spectrometry in biochemistry and medicine.
γ‐Aminobutyric acid (GABA) in human cerebrospinal fluid: radioreceptor assay
TLDR
Using Triton treated membranes and smaller incubation volumes, a radioreceptor assay is described with a sensitivity for GABA levels as low as 1 pmol, which was measured in CSF obtained from patients before and after probenecid treatment.
BIOCHEMICAL EFFECTS IN MAN and RAT OF THREE DRUGS WHICH CAN INCREASE BRAIN GABA CONTENT
TLDR
It is found that approximately 4 times as much AOAA is required by mouth as by parenteral injection to raise brain GABA content in the rat and that DPA given orally produced no alterations of any amino acids in rat brain.
CSF amino acids and plasma‐CSF amino acid ratios in adults 1
SEVERAL groups of investigators have reported mean concentrations of free amino acids in the CSF of adult subjects, using automated ion exchange chromatographic techniques (PERRY & JONES, 1961;
...
...